The Cardiomyopathies Matter Roadmap is the first comprehensive report providing policy solutions to the unmet needs and challenges of cardiomyopathies. It includes key recommendations on how to ensure prompt and accurate diagnosis, promote guidelines-led care, empower patients and families and foster research and innovation at EU and national levels. The Roadmap also looks at leveraging existing legislation and initiatives that can benefit cardiomyopathy patients and supports the call on the EU to go one step further by implementing a dedicated Cardiovascular Health Action Plan, devoting sufficient attention to lesser-known, inherited heart conditions.
The Roadmap was developed based on a review of relevant published and grey literature and input from 10 expert contributors (representing the fields of patient advocacy, cardiology, cardiac nursing and health economics) coming from multiple European countries. To date, the Roadmap has been endorsed by the following organizations:
- ARVC-Selbsthilfe e.V.
- Cardiomyopathy Research the Netherlands
- LMNA cardiac
- Síndromes Arrítmicos relacionados con la Muerte Súbita (SAMS)
In view of the upcoming 2024 European elections, we are now looking forward to extending this support base to ensure that genetically inherited heart conditions such as cardiomyopathies feature amongst the top priorities of current and next political leaders. Cardiomyopathies Matter welcomes the endorsement from any EU or national stakeholders active in the field of cardiovascular health.
To endorse the Roadmap, please send the logo of your organisation in high resolution to the CMatter secretariat (managed by Dentons Global Advisor) at email@example.com
Read the Roadmap: here